Chiesi Usa Patent-Cliff Exposure & CMS Drug Spending Portfolio

Chiesi Usa (US): 11 reconciled FDA prescription therapies (41.2% 2025 to 2030 cliff risk), $258.0M 2024 CMS Part D & Medicaid spend, and 21 CA HCAI SB 17 wholesale price filings.

Regulatory & Reimbursement Dimension Verified Value
Headquarters / ClusterUS
Reconciled FDA Portfolio Therapies11
2025 to 2030 Patent-Cliff Revenue Exposure41.2%
Primary Portfolio LOE Date2027-01-01
2024 CMS Total Public Spend$258.0M
2024 Medicare Part D Spend$80.4M
2024 Medicaid Spend$177.6M
California HCAI SB 17 Filings21 WAC filings (max 22.5% 2-yr change)